Literature DB >> 22542874

Long-lasting transcriptional refractoriness triggered by a single exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine.

R Pattarini1, Y Rong, K R Shepherd, Y Jiao, C Qu, R J Smeyne, J I Morgan.   

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder whose etiology is thought to have environmental (toxin) and genetic contributions. The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine (MPTP) induces pathological features of PD including loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and striatal dopamine (DA) depletion. We previously described the striatal transcriptional response following acute MPTP administration in MPTP-sensitive C57BL/6J mice. We identified three distinct phases: early (5h), intermediate (24h) and late (72h) and reported that the intermediate and late responses were absent in MPTP-resistant Swiss-Webster (SWR) mice. Here we show that C57BL/6J mice pre-treated with a single 40 mg/kg dose of MPTP and treated 9 days later with 4×20 mg/kg MPTP, display a striatal transcriptional response similar to that of MPTP-resistant SWR mice, i.e. a robust acute response but no intermediate or late response. Transcriptional refractoriness is dependent upon the dose of the priming challenge with as little as 10mg/kg MPTP being effective and can persist for more than 28 days. Priming of SWR mice has no effect on their response to subsequent challenge with MPTP. We also report that paraquat, another free radical producer, also elicits striatal transcriptional alterations but these are largely distinct from those triggered by MPTP. Paraquat-induced changes are also refractory to priming with paraquat. However neither paraquat nor MPTP elicits cross-attenuation. Thus exposure to specific toxins triggers distinct transcriptional responses in striatum that are influenced by prior exposure to the same toxin. The prolonged refractory period described here for MPTP could explain at the molecular level the reported discrepancies between different MPTP administration regimens and may have implications for our understanding of the relationship between environmental toxin exposure and PD.
Copyright © 2012 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22542874      PMCID: PMC3371097          DOI: 10.1016/j.neuroscience.2012.03.047

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  60 in total

1.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining.

Authors:  N A Tatton; S J Kish
Journal:  Neuroscience       Date:  1997-04       Impact factor: 3.590

2.  Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

Authors:  R Pattarini; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2007-01-29       Impact factor: 3.590

3.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

Authors:  Francesco Fornai; Oliver M Schlüter; Paola Lenzi; Marco Gesi; Riccardo Ruffoli; Michela Ferrucci; Gloria Lazzeri; Carla L Busceti; Fabrizio Pontarelli; Giuseppe Battaglia; Antonio Pellegrini; Ferdinando Nicoletti; Stefano Ruggieri; Antonio Paparelli; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function.

Authors:  Siobhan Robinson; Pierre Freeman; Cynthia Moore; Justin C Touchon; Lisa Krentz; Charles K Meshul
Journal:  Exp Neurol       Date:  2003-03       Impact factor: 5.330

Review 6.  The gestational environment and Parkinson's disease: evidence for neurodevelopmental origins of a neurodegenerative disorder.

Authors:  Brian K Barlow; Deborah A Cory-Slechta; Eric K Richfield; Mona Thiruchelvam
Journal:  Reprod Toxicol       Date:  2007-02-06       Impact factor: 3.143

7.  Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype.

Authors:  Mona Thiruchelvam; Alison McCormack; Eric K Richfield; Raymond B Baggs; A William Tank; Donato A Di Monte; Deborah A Cory-Slechta
Journal:  Eur J Neurosci       Date:  2003-08       Impact factor: 3.386

Review 8.  Animal models of Parkinson's disease progression.

Authors:  Gloria E Meredith; Patricia K Sonsalla; Marie-Francoise Chesselet
Journal:  Acta Neuropathol       Date:  2008-02-14       Impact factor: 17.088

9.  The mechanism of action of MPTP and MPP+ on endogenous dopamine release from the rat corpus striatum superfused in vitro.

Authors:  G D Chang; V D Ramirez
Journal:  Brain Res       Date:  1986-03-12       Impact factor: 3.252

10.  The impact of gender and estrogen on striatal dopaminergic neurotoxicity.

Authors:  D B Miller; S F Ali; J P O'Callaghan; S C Laws
Journal:  Ann N Y Acad Sci       Date:  1998-05-30       Impact factor: 5.691

View more
  1 in total

1.  Low-variance RNAs identify Parkinson's disease molecular signature in blood.

Authors:  Maria D Chikina; Christophe P Gerald; Xianting Li; Yongchao Ge; Hanna Pincas; Venugopalan D Nair; Aaron K Wong; Arjun Krishnan; Olga G Troyanskaya; Deborah Raymond; Rachel Saunders-Pullman; Susan B Bressman; Zhenyu Yue; Stuart C Sealfon
Journal:  Mov Disord       Date:  2015-03-18       Impact factor: 10.338

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.